Nantes University Hospital: Leukemia, Myeloid, Acute trials

The registry lists 12 Leukemia, Myeloid, Acute studies with Nantes University Hospital as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 4Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of NK Cells in the Monitoring of Patients With Acute Leukemia or MyelodysplasiaNot yet recruitingNCT07249476
• Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive ChemotherapyRecruitingNCT06439199
• Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingNCT05917405Phase 2
• Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMRecruitingNCT05697510Phase 1
• Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04886206Phase 1
• Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid LeukemiaCompletedNCT04641910
• Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)CompletedNCT04547062Phase 1
• VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT01541280Phase 2
• Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)Status unknownNCT01146262Phase 1/2
• Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell TransplantationCompletedNCT01015196Phase 2/3
• Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskCompletedNCT00860639Phase 3
• Natural Killer Index From Hematopoietic Stem Cell GraftCompletedNCT00435864Not applicable